Oct 3 (Reuters) - RedHill Biopharma Ltd said on Tuesday its drug to treat diarrhea-predominant irritable bowel syndrome (IBS-D) met the main goal in a mid-stage study, with patients showing improvement in stool consistency.
The drug met the main goal but did not show enough promise in improving abdominal pain and overall response in patients.
The trial was testing a 12-mg dose of the once-daily oral drug, Bekinda, in patients with IBS-D, against a placebo.
U.S.-listed shares of the Tel Aviv-based company were down about 3 percent at $10.50 in premarket trading on Tuesday.
RedHill is also testing Bekinda for the treatment of acute gastroenteritis and gastritis.
The company said it intends to start a late-stage study for the drug and plans to meet with the U.S. Food and Drug Administration by early next year to discuss the path towards potential marketing approval.
Up to 30 million Americans suffer from IBS, out of which over 50 percent are cases of IBS-D.
In June, Bekinda met the main goal of a late stage trial in patients with gastroenteritis - inflammation of the stomach and intestines that causes vomiting and diarrhea. (Reporting by Divya Grover in Bengaluru; Editing by Bernard Orr)